Prosecution Insights
Prosecution Insights
Tech Center 3600 • Art Units: 1685 3676
This examiner grants 46% of resolved cases
Dawn Marie Bickham is an examiner in Tech Center 1600, specifically within Art Unit 1685. The examiner has 39 resolved cases on record. These 39 resolved cases result in an allowance rate of 46.2 percent. This 46.2 percent allowance rate serves as a metric for practitioners evaluating their chances of success. Understanding this rate is a component of setting expectations during the stages of patent prosecution.
The median days to allowance for Bickham is 1574. This 1574-day timeline provides a measure of the duration required to reach a grant. Practitioners should also consider the 64.2 percent interview lift. An interview lift of 64.2 percent suggests that engaging in a direct discussion with the examiner is associated with an increased probability of allowance. This 64.2 percent lift is a factor to include in prosecution planning.
In Art Unit 1685, the 1574 median days to allowance and 46.2 percent allowance rate define the examiner's historical performance. The 64.2 percent interview lift indicates that interviews are a relevant tool for applicants. With 39 resolved cases, the data provides a specific statistical context for Tech Center 1600. Practitioners can use these figures to refine their approach and manage client expectations regarding the 1574-day median timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17765929 | STRESS ANALYSIS APPARATUS, STRESS ANALYSIS METHOD, AND COMPUTER-READABLE RECORDING MEDIUM | Final Rejection | NEC Corporation |
| 16278611 | GAN-CNN FOR MHC PEPTIDE BINDING PREDICTION | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 18479416 | A PEPTIDE BASED VACCINE GENERATION SYSTEM WITH DUAL PROJECTION GENERATIVE ADVERSARIAL NETWORKS | Non-Final OA | NEC Laboratories America, Inc. |
| 17510882 | PEPTIDE-BASED VACCINE GENERATION | Final Rejection | NEC Laboratories America, Inc. |
| 18089565 | IDENTIFICATION SYSTEM OF CIRCULATING BIOMARKERS FOR CANCER DETECTION, DEVELOPMENT METHOD OF CIRCULATING BIOMARKERS FOR CANCER DETECTION, CANCER DETECTION METHOD AND KIT | Final Rejection | Industrial Technology Research Institute |
| 18026376 | PREDICTING PROTEIN STRUCTURES BY SHARING INFORMATION BETWEEN MULTIPLE SEQUENCE ALIGNMENTS AND PAIR EMBEDDINGS | Non-Final OA | DeepMind Technologies Limited |
| 17434455 | METHODS FOR DETERMINING A DESIGNABLE REGION OF OLIGONUCLEOTIDES | Final Rejection | SEEGENE, INC. |
| 18477346 | COPY NUMBER VARIATION (CNV) BREAKPOINT DETECTION | Non-Final OA | Illumina, Inc. |
| 18301595 | TARGETED CALLING OF OVERLAPPING COPY NUMBER VARIANTS | Non-Final OA | Illumina, Inc. |
| 17556493 | LIFECYCLE ASSESSMENT SYSTEMS AND METHODS FOR DETERMINING EMISSIONS FROM ANIMAL PRODUCTION | Final Rejection | Low Carbon Technologies, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy